Comparative Pharmacology
Head-to-head clinical analysis: NEO FRADIN versus SYNERCID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO FRADIN versus SYNERCID.
NEO-FRADIN vs SYNERCID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis. It also disrupts bacterial cell membrane integrity.
Synercid is a combination of two streptogramin antibiotics, quinupristin and dalfopristin, which bind to the 50S bacterial ribosome and inhibit protein synthesis. Quinupristin binds to the 23S rRNA near the peptidyl transferase center, while dalfopristin binds to a nearby site and enhances quinupristin's binding. The synergistic effect results in irreversible inhibition of bacterial protein synthesis.
50-100 mg/kg/day orally in 3-4 divided doses. Maximum 3 g/day.
7.5 mg/kg IV every 8 hours, administered as a 60-minute infusion.
None Documented
None Documented
2-3 hours in normal renal function; prolonged to 24-30 hours in anuria or severe renal impairment; no significant change in hepatic disease.
The terminal elimination half-life is approximately 0.85 hours for dalfopristin and 1.3 hours for quinupristin; however, the active metabolite of quinupristin has a half-life of about 3.5 hours, supporting twice-daily dosing.
Renal: >90% unchanged drug via glomerular filtration, with small amount reabsorbed; biliary/fecal: <2%.
Primarily hepatic metabolism with biliary excretion; approximately 15% of the dalfopristin dose and 32% of the quinupristin dose are excreted unchanged in feces; renal excretion is minor (<5% for both components).
Category C
Category C
Antibiotic
Antibiotic